Madison-based TomoTherapy is being sold to Accuray in a deal valued at about $277 million, it was announced Monday. The companies signed a definitive agreement that calls for Accuray to buy TomoTherapy for $4.80 per share in cash and stock. The companies said the transaction will create a premier radiation oncology company.
(TomoTherapy was a university-based start-up company co-founded by UW-Madison researchers Rock Mackie and Paul Reckwerdt.)
TomoTherapy was